Australian Minister for Health Sussan Ley today launched a three-pronged approach to support and promote dementia research in the search of new treatments, models of care and ways of preventing the debilitating disease.
Ms Ley announced A$35.6 million ($25.8 million) for six Dementia Research Team Grants that included the largest dementia clinical trial in the world for people aged 55 to 75 to test an online tool to reduce the risk of dementia, and projects aimed to uncover early warning signs of Alzheimer’s and non-Alzheimer’s disease dementias earlier.
Ms Ley said the six grants were a significant part of a A$200 million Abbott government election commitment to dementia research and ensured Australia remained at the forefront of international best practice.
“This A$35.6 million Abbott Government commitment to dementia research is essential as the number of Australians with dementia is predicted to grow to over one million people in the next 40 years,” Ms Ley said, adding: “The significant investment will focus Australian research teams on finding innovative new models of care for dementia, treatments and ways of preventing the disease. Importantly these Dementia Research Team Grants provide a new opportunity for Australian researchers to collaborate on priorities, rather than compete as individuals.”
National Institute for Dementia Research to be established
Today, Ms Ley also announced that Alzheimer's Australia had won the contract to establish and run the National Health and Medical Research Council’s A$50 million National Institute for Dementia Research.
The establishment of the National Institute for Dementia Research is in line with the government’s commitment to boosting dementia research in Australia and will specifically ensure better integration with international research and a focus for rapid translation of evidence from paper to policy and practice.
To support the work of the Institute, Ms Ley also released the NHMRC National Dementia Research & Translation Priority Framework that highlights five national dementia priorities. Ms Ley said the priorities had been finalized following broad consultation with researchers, carers, medical practitioners and people with dementia and prioritizes research into prevention, diagnosis, treatment, care, and improving the quality of life for people living with dementia.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze